2. Signaling Pathways
  3. GPCR/G Protein
    MAPK/ERK Pathway
  4. Ras
  5. Ras Modulator

Ras Modulator

Ras Isoform Comparison

Ras Modulators (6):

Cat. No. Product Name Effect Purity
  • HY-116428
    L-744832
    		Modulator
    L-744832 is a farnesyl transferase inhibitor. L-744832 effectively inhibits the farnesylation of H-Ras and N-Ras, but has little effect on K-Ras treatment. L-744832 not only directly targets the oncogenic pathway by inhibiting Ras farnesylation, but also enhances radiosensitivity by restoring TGF-β signaling through epigenetic reprogramming. L-744832 can induce cell cycle arrest and apoptosis. L-744832 can be used in combination therapy studies for Ras-driven tumors such as pancreatic cancer.
  • HY-152951
    Palmostatin M
    		Modulator
    Palmostatin M is a Ras signaling modulator that targets acyl-protein thioesterase 1 (APT1) and 2 (APT2) in cells, with an IC50 of 2.5 nM for APT1. Palmostatin M interferes with the depalmitoylation cycle of Ras and downregulates the overall Ras signaling pathway. Palmostatin M can be used in cancer-related research.
  • HY-153555
    KRAS G12D modulator-1
    		Modulator
    KRAS G12D modulator-1 (compound 6) is a potent KRAS G12D modulator with IC50 values of 1-10 μM for NEA-G12D, PPI-G12D, and p ERK-AGS, respectively. KRAS G12D modulator-1 can be used in research of cancer.
  • HY-148878
    Ras modulator-1
    		Modulator
    Ras modulator-1 is a modulator of Ras. Ras modulator-1 is an active compound extracted from patent US20120302581.
  • HY-121459
    Neoantimycin
    		Modulator
    Neoantimycin is a GRP78/BiP and K-Ras regulator with anticancer activity. Its biosynthesis is catalyzed by a hybrid nonribosomal peptide synthetase/polyketide synthase (NRPS/PKS) system.
  • HY-120885
    (+)-Oxanthromicin
    		Modulator
    (+)-Oxanthromicin (Compound 1) mislocalizes the oncogenic mutant K-Ras from the plasma membrane of intact Madin-Darby canine kidney (MDCK) cells, and exhibits thereby antitumor efficacy.